Purpose: Comorbid chronic conditions are thought to be common in osteoarthritis (OA) patients, particularly mobility-related conditions such as cardiovascular disease (CVD) and diabetes. The impact of OA on these comorbidities and the relationship to mortality is poorly understood. The purpose of this review is to identify systematic reviews (SR)/meta-analyses (MA) that correlate OA and diabetes, CVD and mortality focusing on methodological features and strength of association. Methods: Two focused searches were conducted to find recent SRs/MAs that examined the association between OA and diabetes or CVD (PubMed and Embase, from inception to April 2018) and mortality (PubMed, from inception to September 2018). Supplementary searches were conducted by searching the internet and checking reference lists of identified articles. Only papers published in English were eligible. Both absolute and relative effects as reported in each SR/MA were extracted, with priority given to estimates based on multivariate models (OA versus non-OA) controlling for confounders. Results: Our search initially identified 2,874 records, and after screening, 7 SRs/MAs met inclusion criteria. Of these, one examined the relationship between OA and diabetes (N=49 studies, with over 1 million patients) and two examined CVD (N=16 unique studies, with ∼260,000 patients). For mortality, 3 SRs/MAs were identified (N=17 unique studies, with ∼273,000 patients) and one that conducted an individual patient data MA. The SRs/MAs included high to moderate quality studies that generally controlled for confounders (most often, age and sex). The single review on diabetes identified a statistically significant association between OA and diabetes (OR 1.41, 95% CI: 1.21 to 1.65) (Table 1). Both reviews on CVD also found a significant association between OA and CVD with pooled estimates ranging from a risk ratio (RR) of 1.24 (95% CI: 1.12 to 1.37) to 1.69 (95% CI: 1.13 to 2.53). Neither review that examined OA (any site) and all-cause mortality found a significant association, however the MA of individual patient data found that in U.S. patients, hip and knee OA were associated with increased risk of premature mortality. Two reviews reported that OA was significantly associated with cardiovascular-related death.Table 1Summary of findings based on meta-analyses of OA and comorbidities/mortality (based on multivariate models)PopulationComorbidityAbsolute effect (OA vs. Non-OA)Relative effect (95% CI)1No. studies included in each analysis (total sample size)Any OADiabetesNROR 1.41 (1.21, 1.65)20 (1,040,175)Any OA (sensitivity analysis)2DiabetesNROR 1.32 (1.13, 1.53)5 (9,947)Hand OADiabetesNROR 1.31 (1.07, 1.61)NRHip OADiabetesNROR 0.71 (0.49, 1.04)3 (6,240)Knee OADiabetesNROR 1.51 (1.09, 2.09)5 (9,102)Any OACVDNRRR 1.24 (1.12, 1.37)15 (102,944)Any OACVD38% vs. 9%RR 1.69 (1.13, 2.53)4 (176,358)Any SOACVDNRRR 1.47 (0.91, 2.39)3 (6,037)Any ROACVDNRRR 1.23 (1.02, 1.48)7 (25,362)Hand OACVDNRRR 1.03 (0.85, 1.25)5 (15,728)Hip OACVDNRRR 1.23 (1.11, 1.38)3 (13,968)Knee OACVDNRRR 1.30 (1.00, 1.69)4 (7,796)Any OAHFNRRR 1.40 (1.13, 1.73)5 (87,500)Any OAHF5% vs. 2%RR 2.80 (2.25, 3.49)2 (13,096)Any OAIHDNRRR 1.33 (1.20, 1.46)8 (177,253)Any OAIHD9% vs. 4%RR 1.78 (1.18, 2.69)2 (13,952)Any OAStroke4% vs. 9%RR 1.00 (0.13, 7.87)3 (175,575)Any OAStrokeNRRR 1.11 (0.96, 1.29)6 (151,321)Any OAMI4% vs. 7%RR 0.69 (0.05, 8.98)2 (174,227)Any OATIA2% vs. 6%RR 0.33 (0.27, 0.41)1 (162,479)Any OAAll-cause mortalityNRHR 1.10 (0.97, 1.25)7 (28,559)Any SOAAll-cause mortalityNRHR 0.91 (0.68, 1.23)7 (NR)Any ROAAll-cause mortalityNRHR 1.13 (0.95, 1.35)6 (NR)Hip SOA (U.S.)All-cause mortalityNRHR 1.20 (1.04, 1.37)2 (11,900)Knee SROA (U.S.)All-cause mortalityNRHR 1.23 (1.07, 1.42)2 (4,156)Non-site specific OAAll-cause mortalityNRHR 1.18 (1.08, 1.28)4 (NR)Hand OAAll-cause mortalityNRHR 1.18 (1.07, 1.30)4 (NR)Any OACV deathNRRR 1.53 (1.27, 1.84)6 (16,109)Any OACV death14% vs. 9%HR 1.21 (1.10, 1.34)4 (14,227)Note. Bolded results are statistically significant. All data are summarized from previous reviews. If two reviews reported on the same outcome, both estimates are provided. CVD, cardiovascular disease; HF, heart failure; IHD, ischemic heart disease; MI, myocardial infarction; NR, not reported; ROA, radiographic OA; SOA, symptomatic OA; SROA, symptomatic radiographic OA; TIA, transient ischemic attack; U.S., United States. OR, odds ratio; RR, risk ratio; HR, hazard ratio. 1 Pooled estimate based on meta-analysis. 2 Only studies that used an internationally recognized diagnosis criteria for OA such as ACR criteria or the KL score for OA definition. Open table in a new tab Note. Bolded results are statistically significant. All data are summarized from previous reviews. If two reviews reported on the same outcome, both estimates are provided. CVD, cardiovascular disease; HF, heart failure; IHD, ischemic heart disease; MI, myocardial infarction; NR, not reported; ROA, radiographic OA; SOA, symptomatic OA; SROA, symptomatic radiographic OA; TIA, transient ischemic attack; U.S., United States. OR, odds ratio; RR, risk ratio; HR, hazard ratio. 1 Pooled estimate based on meta-analysis. 2 Only studies that used an internationally recognized diagnosis criteria for OA such as ACR criteria or the KL score for OA definition. Conclusions: This review demonstrates an association between OA and mobility related comorbidities based on evidence assessed as generally high quality. Overall, OA is associated with higher risk of both diabetes and CVD, with knee OA being most closely related. In addition, there is evidence to suggest an association between knee and hip OA and all-cause mortality as well as mortality from cardiovascular causes. There is insufficient evidence to draw conclusions regarding causation.